This top ASX healthcare stock has moved into the fast lane boosted by recent positive developments. So much so, that it is now opening excellent further long term growth potential.
Telix Pharmaceuticals (ASX: TLX)
Telix Pharmaceuticals welcomed a landmark decision from the U.S. Centers for Medicare & Medicaid Services to start separate payments for specialized diagnostic radio pharmaceuticals for Medicare Fee-for-Service patients in hospital outpatient settings. Beginning from 2025, this change will allow equal access to advanced imaging agents with purchase decisions based on clinical demand rather than reimbursement dynamics. The new payment framework will provide consistent reimbursement rates for diagnostic agents like Illuccix®, as well as for other investigational products in Telix’s pipeline, enhancing accessibility for patients and hospitals.
In a related development, Telix announced that the FDA has accepted its New Drug Application (NDA) for TLX101-CDx (Pixclara®), a novel imaging agent for glioma. This agent was granted priority review status, with a target date for a decision set for April 26, 2025. Pixclara aims for better diagnosis and management of gliomas, one of the major types of brain tumors, with refined imaging capabilities than conventional techniques. If approved, this would represent considerable progress in brain cancer imaging, given this poses a significant unmet medical need for patients.
Telix also delivered glowing third-quarter financial results in 2024, with revenues above AU$200 million, driven largely by sales of its prostate cancer imaging agent, Illuccix®. This reflects a significant improvement from prior quarters and bodes well for the company's market presence in the field of Urology.
On the therapeutics front, Telix is advancing its clinical programs across various cancer treatments. The ProstACT GLOBAL trial for TLX591, a prostate cancer therapy, is enrolling patients in the U.S. and Asia Pacific. Additionally, TLX250 for kidney cancer has established its maximum tolerated dose in clinical trials, and TLX101 therapy for brain cancer has shown promising results in early studies. These developments highlight Telix's commitment to enhancing patient outcomes through innovative targeted therapies.
Telix is also expanding its manufacturing capabilities, having announced the acquisition of RLS (USA) Inc., which will enhance its production footprint in North America. This strategic move aims to establish a robust network for producing radiopharmaceuticals at scale. Furthermore, the company is progressing with regulatory submissions for various imaging agents globally, including Illuccix® and TLX250-CDx. These efforts are geared toward improving patient access to essential diagnostic tools while maintaining high manufacturing standards across its facilities.
(Source: Company’s Report)
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.